Skip to main content

Balaji Amines Reports Q1 Net Profit Of ₹74.9 Crore, Up From ₹38 Crore YoY

Balaji Amines' consolidated Q1 FY27 profit surged by 97.11% YoY to ₹74.9 crore, supported by a 27.37% growth in operating revenue. EBITDA margins expanded by 1,015 bps to 25.41%, indicating improved capacity utilization and cost absorption as its newly commissioned Dimethyl Ether plant begins scaling.

Author Image
Sahi Markets
Published: 28 Jul 2026, 06:45 AM IST (0 month ago)
Last Updated: 28 Jul 2026, 06:45 AM IST (0 month ago)
2 min read
Reviewed by Arpit Seth

Market snapshot: Balaji Amines delivered an exceptionally strong performance in Q1 FY27, marked by a massive operational turnaround. The company recorded a sharp surge in profitability and revenue growth, signaling robust recovery and successful execution of its expansion initiatives.

Data Snapshot

  • Consolidated Net Profit increased by 97.11% YoY to ₹74.9 crore, up from ₹38.0 crore in the corresponding quarter of the previous year.
  • Consolidated Revenue from Operations grew 27.37% YoY to ₹456 crore, compared to ₹358 crore in Q1 FY26.
  • Consolidated EBITDA rose 112.07% YoY to ₹116.0 crore, up from ₹54.7 crore in the prior-year period.
  • Operating EBITDA Margin expanded by 1,015 bps to 25.41% from 15.26% YoY, reflecting superior product pricing power.

What's Changed

  • Operating trajectory turned highly positive with net profit rising by 97.11% YoY, breaking a multi-quarter trend of margin compression.
  • The newly commissioned 1,00,000 TPA Dimethyl Ether plant at Solapur is transitioning from capital expense to an active revenue stream, offering import substitution solutions.

Key Takeaways

  • Topline and bottom-line growth outperformed historical averages, with revenue surging to ₹456 crore and EBITDA more than doubling to ₹116 crore.
  • EBITDA margins climbed to a strong 25.41%, driven by favorable domestic demand in core amine derivatives and a stabilizing input cost environment.
  • The company successfully completed commercialization of India's first commercial-scale DME plant in Q1, solidifying its status as a single-source domestic supplier.

SAHI Perspective

The outstanding Q1 FY27 performance validates Balaji Amines' strategy of expanding into niche, import-substituting segments. By becoming the exclusive domestic commercial manufacturer of Dimethyl Ether in India, the company is positioning itself at the forefront of the alternative fuel and propellant market, which should yield superior, sustainable margins.

Market Implications

These blockbuster earnings are highly supportive of a valuation re-rating. Market participants are likely to respond favorably to the 1,015 bps margin expansion, validating that the specialty chemicals sector is emerging from its cyclical bottom.

Trading Signals

Market Bias: Bullish

Strong bias driven by a 97.11% YoY net profit jump to ₹74.9 crore and a massive expansion in operating margins to 25.41%, indicating a definitive structural recovery.

Overweight: Specialty Chemicals, Alternative Fuels, EV Battery Chemistry

Trigger Factors:

  • Volume ramp-up and pricing realizations from the 1,00,000 TPA DME facility.
  • Commissioning milestones for the Unit-I brownfield expansion expected in H1 FY27.
  • Movement of crude-linked feedstock pricing like methanol.

Time Horizon: Medium-term (3-12 months)

Industry Context

The specialty chemicals industry is seeing structural shifts as Indian players substitute imports with domestic production. Revised BIS standards allowing up to 8% DME blending in LPG open up immediate, high-volume domestic market opportunities for local chemical manufacturers.

Key Risks to Watch

  • Volatility in crude-linked raw material costs that could impact the operating delta.
  • Potential pricing pressure if Chinese chemical competitors restart aggressive dumping practices.
  • Awaiting remaining regulatory approvals for full commercial logistics of cylinder-filling and transportation.

Recent Developments

Balaji Amines successfully commissioned India's first commercial-scale 1,00,000 TPA Dimethyl Ether (DME) plant in Solapur, Maharashtra, with production commencing on May 20, 2026. Further, the subsidiary Balaji Speciality Chemicals is executing a ₹750 crore expansion, with the Unit-I brownfield EDA-based expansion scheduled for commissioning in H1 FY27, and the Unit-II greenfield project scheduled for Q4 FY27.

Closing Insight

Balaji Amines' stellar first-quarter performance indicates that its operational and strategic levers are fully aligned. The combination of core chemical margin expansion and pioneering clean fuel manufacturing creates a highly resilient platform for future growth.

High Performance Trading with SAHI.

Disclaimer: This news section may include AI-generated or AI-assisted news, summaries, drafts, or insights. All content is subject to human review before publication. While we aim for accuracy, readers should independently verify information before relying on it.

Open Free Account

Frequently Asked Questions (FAQs)

All topics

Add Sahi as a Preferred Source on Google

Click the link, confirm the box next to sahi.com is checked — ignore any other results.